The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease
- PMID: 3742715
- DOI: 10.1007/BF00256702
The activity of phosphohexose isomerase in primary breast carcinomas and response to chemotherapy in patients with metastatic disease
Abstract
The activity of phosphohexose isomerase [PHI] was measured in 48 primary carcinomas from patients with breast cancer, and its usefulness as a predictor of response to cytotoxic drugs at the metastatic stage was evaluated. There was a statistically significant difference in the activity of PHI between responders and non-responders to these treatments. These preliminary findings are currently being evaluated in an extended series.
Similar articles
-
[Prognostic significance of serum phosphohexose isomerase in metastatic breast cancer].Med Klin (Munich). 1987 May 15;82(11):385-91. Med Klin (Munich). 1987. PMID: 3600541 German. No abstract available.
-
Relationship of glycolytic enzyme activities and response of breast cancer patients to chemotherapy: A preliminary report.Cancer. 1976 Aug;38(2):695-700. doi: 10.1002/1097-0142(197608)38:2<695::aid-cncr2820380213>3.0.co;2-f. Cancer. 1976. PMID: 974990
-
Evaluation of phosphohexose isomerase as a metastasis marker in breast cancer patients.Eur J Gynaecol Oncol. 1997;18(5):397-9. Eur J Gynaecol Oncol. 1997. PMID: 9378161
-
Current management of metastatic breast cancer.Semin Oncol. 1999 Aug;26(4 Suppl 12):1-10. Semin Oncol. 1999. PMID: 10482189 Review.
-
[Possibility that AMF will serve as a target molecule for the diagnosis and treatment of a metastatic neoplasm].Yakugaku Zasshi. 2005 Feb;125(2):169-75. doi: 10.1248/yakushi.125.169. Yakugaku Zasshi. 2005. PMID: 15684571 Review. Japanese.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical